Skip to main content
OpenTrials
Completed

NCT Number: NCT00918606

An Evaluation of the Pharmacokinetics and Safety of LIPO-102 in Healthy Volunteers

An Evaluation of the PK and Safety of LIPO-102 in Healthy Volunteers.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Subcutaneous Adipose Tissue Reduction

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Baltimore, Maryland, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and non pregnant female
  • 18-55 years old
  • Sufficient abdominal fat for injections
  • Signed informed consent

Exclusion criteria

  • Known hypersensitivity to study drugs
  • Treatment with an investigational agent within 30 days before first dose

Treatment and study plan

LIPO-102

Drug

LIPO-102

Primary outcomes

  1. Safety: Laboratory tests, medical exams

    Time frame: 4 weeks

Secondary outcomes

  1. Pharmacokinetics

    Time frame: 24 hours

Sponsors and collaborators

Lead sponsor

Neothetics, Inc

Industry

Registry information

Important dates

Study start
2009
Primary completion
2009
Study completion
2009
First posted
Jun 11, 2009
Registry last updated
Mar 24, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.